Chairs: Asgeir Jakola, Matthias Simon
JS04.1 Lessons learned from ReSurge
Philippe Schucht, Switzerland
JS04.2 Ethics of randomisation in the field of surgery
Marike Broekman, Netherlands
JS04.3 What can surgery learn from other disciplines in terms of trial design?
Roberta Ruda, Italy
Chairs: Andrada Turcas, Barbara Kiesel
JS03.1 Targeted therapies in pediatric brain tumors paving the way for adult patients
Marcel Kool, Netherlands
JS03.2 Molecular testing and treatment of young adults with CNS tumors
Angela Mastronuzzi, Italy
JS03.3 Late toxicity and long term morbidity in adult survivors of a CNS tumor during childhood or adolescence
Katrin Scheinemann, Switzerland
JS03.4 Pediatric-type brain tumors in adults
Peter Hau, Germany
Chairs: Giuseppe Minniti, tbc
Chairs: tbc
WS02.1 Group A: Clinical trial Editor
Ulrike Harjes, United Kingdom (Nature Medicine)
WS02.2 Group A: Clinical trial Researcher
Michael Weller, Switzerland
WS02.3 Group B: Basic science Editor
Alexia-Ileana Zaromytidou, United States (Nature Cancer)
WS02.4 Group B: How to publish successfully: The perspective of a basic science researcher
Michael Platten, Germany
WS02.5 Group C: How to publish: The editor’s perspective on translational science
Sara Hamilton, United States (Cell reports Medicine)
WS02.6 Group C: How to publish successfully: The perspective of a translational science researcher
Mariella Filbin, United States
WS02.7 Group D: How to publish: The editor’s perspective on translational science
Kathy Miller, United States (JCO)
WS02.8 Group D: How to publish: The scientist’s perspective on translational science
Emeline Tabouret, France
WS02.9 Group E: How to write grants successfully
Susan Chang, United States (Neuro-Oncology)
WS02.10 Group E: How to write grants successfully: The perspective of a researcher
Dieter Henrik Heiland, Germany
Chairs: Linda Douw, George Petrescu
Chairs: Roberta Ruda, Pim French
KS02.1 Overview, update and recent findings of the INDIGO trial
Patrick Wen, United States
KS02.2 The role of IDH inhibitors in relation to standard of care for IDH mutated gliomas
Martin van den Bent, Netherlands
KS02.3 Effects of IDH inhibitors on quality of life and seizure control
Katherine Peters, United States
KS02.4 Molecular and cellular effects of IDH inhibitors
Marc Sanson, France
Chairs: Amanda Fitzpatrick, Mihaela Lorger
OS03.1 Vulnerabilities of dormant/ latent cancer cells
Srinivas Malladi, United States
OS03.2 Vulnerabilities of senescent cancer cells
Isabelle Le Roux, France
OS03.3 Senolytic drug development
Terry Burns, United States
Chairs: Maximilian Mair, tbc
OS04.1 The hormone-sensitivity of glioma and the question of pregnancy
Héléne Dumond, France
OS04.2 Navigating Parenthood: Challenges of Living with a Brain Tumor
Emma Nicklin, United Kingdom
OS04.3 Fertility preservation in women with CNS tumors
Alicia Tosoni, Italy
OS04.4 Fertility, a brain tumour and me
Shona Floyd, United Kingdom
For more information 
click here.
Susan Short, United Kingdom
President EANO
Anthony Chalmers, United Kingdom
President EANO Meeting 2024
Manuel Valiente, Spain
Chair EANO Scientific Committee
Chairs: Susan Short, Anthony Chalmers
PL01.1 A framework for understanding white matter invasion
Francesco Latini, Sweden
PL01.2 Multiscale network neuroscience in brain tumor patients
Linda Douw, Netherlands
PL01.3 Remote neuronal activity promotes glioblastoma progression and brain network hyperactivity
Benjamin Deneen, United States
Chairs: Karin Piil, Isabelle Ryden
OS02.1 Psychological therapies for symptom control
Martin Klein, Netherlands
OS02.2 Exercise for symptom management
Karin Gehring, Netherlands
OS02.3 Carer preparedness for carers of patients with high-grade glioma: RCT results
Georgia Halkett, Australia
Chairs: tbc
JS02.1 Interplay between DDR and immune response in glioma
Maria Castro, United States
JS02.2 Early phase clinical trials of DDR inhibitors in glioblastoma-state of play
Anthony Chalmers, United Kingdom
JS02.3 Preclinical evaluation of the neuroprotective effects of DDR inhibitors following brain irradiation
Kaye Williams, United Kingdom
JS02.4 Exploiting MGMT and other DNA repair deficiencies in glioma to induce tumour specific DNA damage
Ranjit S. Bindra, United States
Chairs: Magnus Essand, Dieter Henrik Heiland
KS01.1 Boosting immunity using radiotherapy
Kathryn Beal, United States
KS01.2 Gut-brain axis in glioblastoma
Francisco Quintana, United States
KS01.3 Diet, microbiome and immunity
Anne-Katrin Pröbstel, Switzerland
Chairs: Philipp Lohmann, Matthijs van der Meulen, Dan Mitrea
WS01.1 Introduction of CBI
Marjolein Geurts, Netherlands
WS01.2 Charting the Path to Independence: What can EANO do for you?
Susan Short, United Kingdom
WS01.3 Time management – Tips and Tricks to Combine Clinical and research duties
Michael Platten, Germany
WS01.4 People management – Effective Student Mentoring
Matthias Preusser, Austria
WS01.5 Introduction of knowledge market
Johnny Duerinck, Belgium
WS01.5.A Molecular pathology/The Heidelberg classifier
Abigail Suwala, Germany
WS01.5.B Storage and processing of large datasets
Philipp Vollmuth, Germany
WS01.5.C Mouse models for glioma research
Leila Akkari, Netherlands
WS01.5.D Neurosurgical trials in oncology
Asgeir Jakola, Sweden
Chairs: Isabel Arrillaga-Romany, Felix Sahm
ME01.1 Clarification on the WHO Classification 2021
Pieter Wesseling, Netherlands
ME01.2 New Tumor Types
Cynthia Hawkins, Canada
ME01.3 Use of methylation profiling
Pascale Varlet, France
Chairs: Matthias Preusser, Martin Taphoorn
ME02.1 Neuro-Oncology Journal
Susan Chang, United States
ME02.2 Neuro-Oncology Advances Journal
Gelareh Zadeh, Canada
ME02.3 Neuro-Oncology Practice Journal
Martin Taphoorn, Netherlands
Chair: Karin Piil, Lena Rosenlund
ME03.1 Neuro-oncological Patient and Caregiver Advisory Group in a Proton therapy dose finding trial
Anouk Kirsten Trip, Denmark
ME03.2 How to measure the effect from PPI in research- The Patient Engagement In Research Scale (PEIRS-22)
Clayon Hamilton, Canada
ME03.3 The impact of patient involvement in neuro oncological research
Helen Bulbeck, United Kingdom
EANO Meeting - Friday, October 18, 2024
Note that the programme is subject to change and will be continuously updated.
All times below refer to British Summer Time (BST).